Discover a smarter way to manage and share market access resources with local affiliates Are your global market access resources scattered, leading to inconsistencies and confusion among your affiliates? Join...
Read More
What do global market access teams need to know about the US market? What do US payers expect to hear from Pharma and Medtech companies? What kind of value messaging...
Read More
Discover our top picks for must-attend sessions at the World EPA Congress 2025 in Amsterdam. Enhance your understanding of core topics with our recommended pre-reading materials
Discover Sophie Streeton’s career journey and her decision to join Mtech Access. Learn about her early experiences in the Global Market Access Team. Sophie leverages her expertise in health policy, medical writing, and market access.
We are delighted to announce that Clare Foy (Director – Global Market Access), Hannah Palin (Director – Local Market Access), and Calum Jones (Associate Director – Health Economics) will be...
Read More
Global healthcare faces growing pressures. We explore how HEOR is evolving in 2025 to deliver value, meet payer needs, and support market access decisions.
Will Battershill and Hollie Wheat from Delta Hat discuss key insights into HTA decision-making from ISPOR Europe. Will explores the hot topic of incorporating patient and carer perspectives into decision-making, whilst Hollie dives into the use of surrogate endpoint evaluation in HTA decision-making.
In this four-part series, we will explore the various challenges facing orphan medicines entering the European market and suggest solutions that can help improve patient access. In the final part...
Read More
Challenges for orphan medicines entering the European market – Part 3: Economic evidence development
In this four-part series, we will explore the various challenges facing orphan medicines entering the European market and offer solutions that can help improve patient access. In Part 3 of...
Read More
Challenges for orphan medicines entering the European market – Part 2: Clinical evidence development
In this four-part series, we will explore the various challenges facing orphan medicines entering the European market and offer solutions that can help improve patient access. In Part 2 of...
Read More
